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Many animal models of human hemorrhagic disorders have 
been described,32 including severe hemophilia A,15,18,24,31 severe he-
mophilia B,12,35 and von Willebrand disease in dogs;10,33 sheep with 
hemophilia A;38 factor VIII and factor IX knockout mice;2,26,28,48 rats 
with hemophilia A;4,5,34 and pigs with von Willebrand disease.14,20 
All have phenotypic features of severe hemorrhage disease analo-
gous to human disease and have various advantages for studying 
gene therapy, factor replacement therapy, immune tolerance, and 
curative organ transplantation.40
An inversion of the factor VIII gene analogous to one common-
ly found in humans with severe hemophilia A has been described 
in at least 2 independent dog colonies.24,31 These dogs have been 
used to test gene therapy, factor VIII replacement therapy, inhibi-
tor development, and the induction of immune tolerance to treat 
factor VIII inhibitors. Evidence indicates that, in humans, the like-
lihood of factor VIII inhibitor development depends in large part 
on the type of mutation that causes hemophilia A.17,36 Whether 
polymorphisms in the amino-acid sequence of the factor VIII 
gene that are not related to the hemophilia mutation contribute to 
inhibitor risk47 is a topic of debate.21,44
We study the immunogenicity of factor VIII with mismatches in 
amino acids of the factor VIII protein in dogs with hemophilia A due 
to the gene inversion involving intron 22. These dogs have poly-
morphic forms of factor VIII that differ from the normal, consen-
sus sequence at amino acids 909 and 1184 of the mature protein.6,24,31 
These polymorphic sites differ from normal canine factor VIII that is 
transfused to treat bleeding in hemophilic dogs and may represent 
novel epitopes that can be recognized in recipients of mismatched 
donor factor VIII. As part of our studies of hemophilia A and the im-
munogenicity of the factor VIII protein, we have sought to identify 
dogs with hemophilia A due to mutations other than the intron 22 
gene inversion, to study the immune response to ‘foreign’ proteins 
in the setting of other factor VIII mutations. We describe here a non-
sense C→T point mutation in a dog with severe hemophilia A and 
no circulating factor VIII activity. Like the dogs with hemophilia A 
due to intron 22 gene inversion, this animal model recapitulates a 
known human mutation that causes hemophilia A.13
Case Report
A male Old English Sheep Dog had frequent severe sponta-
neous bleeding in joints and soft tissues that did not respond to 
vitamin K therapy (empirical treatment for possible inadvertent 
broudifacoum ingestion). Baseline laboratory studies showed 
prolongation of the activated partial thromboplastin and whole-
blood clotting times, with normal prothrombin time and von 
Willebrand factor levels. Results of testing at Cornell University 
Veterinary School showed both the factor VIII activity and anti-
gen were less than 1% of normal, and a diagnosis of severe hemo-
philia A was made (Table 1).
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Genomes BLASTN and BLASTP programs.1 The canine factor 
VIII polypeptide product was numbered with amino acid 1 as 
the alanine residue after the 19-amino-acid signal peptide of the 
protein encoded by the dog factor VIII mRNA (GenBank acces-
sion number, AF016234.6
Restriction endonuclease digests. PCR products from genomic 
DNA were digested with MluCI (recognition sequence, 5′ AATT 
3′) under conditions specified by the manufacturer (New Eng-
land Biolabs, Beverly, MA) before electrophoresis on 1% or 5% 
NuSieve agarose gels (Lonza Rockland, Rockland, ME) prepared 
with TBE buffer (pH 8.2).
Bethesda inhibitor-antibody assay. Neutralizing antibodies to 
factor VIII activity were evaluated by using the Nijmegen modi-
fications to the Bethesda inhibitor assay, in which subject sample 
plasma underwent serial 2-fold dilutions (beginning at 1:2) in 
factor-VIII–deficient plasma; samples then were mixed with pH-
buffered normal pooled canine plasma and incubated for 2 h at 
37 °C, after which residual factor VIII activity was assayed. The 
reciprocal of the dilution at which 50% of the residual factor VIII 
seen in a control reaction (mix of normal plasma and factor VIII 
deficient plasma) remained is defined as the Bethesda inhibitor 
assay titer. This test is typically sensitive to approximately 0.5 
Bethesda inhibitor assay units.11
Factor VIII binding antibody assay. The assay for IgG antibodies 
that bind factor VIII was adapted for canine factor VIII antibody 
detection from a previously published method for quantifying 
IgG antibodies that bind factor VIII in mice.43 Briefly, plates were 
first coated with 0.1 unit recombinant canine factor VIII per well, 
blocked with bovine serum albumin, and dilutions of dog serum 
were then applied to the plate. After washing, bound antifactor 
VIII antibodies were detected by using peroxidase-conjugated 
sheep antidog IgG heavy chain (A40-118P, Bethyl Laboratories, 
Montgomery Texas), goat antidog IgG1 (A40-120P, Bethyl Labo-
ratories), or sheep antidog IgG2 (A40-121P, Bethyl Laboratories). 
After incubation with 3,3′,5,5′-tetramethylbenzidine (peroxidase 
substrate), antibody binding was quantified by measuring the 
absorbance of light at 450 nm after adding sulfuric acid to stop 
the reaction.
Results
Analysis of intron 22 inversion as a potential cause of hemo-
philia A in the subject dog. The first step in our investigation was 
to amplify canine factor VIII cDNA sequence across exons 22 and 
23, a region that is disrupted in dogs with the intron 22 inversion 
previously described in hemophilia A dogs at Chapel Hill31 and 
Queens University.24 Figure 1 A shows amplification of a 236-bp 
product in cDNA from a normal dog and the subject of this study, 
by using primers listed in Table 2. The amplified sequence in the 
subject hemophilia A dog was identical to the normal canine fac-
The dog had 14 bleeding events in 10 mo that required admin-
istration of approximately 10,000 units of factor VIII, prior to his 
donation to the University of North Carolina at Chapel Hill due 
to the high cost of treatment of his bleeding disorder. Since his 
donation, he has had 41 bleeding episodes resulting in 72 treat-
ments with either plasma (2560 units) or recombinant canine fac-
tor VIII (40,168 units) for a total exposure of 42,728 units of factor 
VIII protein.
This dog has been tested for neutralizing antifactor VIII an-
tibodies (by Bethesda inhibitor antibody assay) and for factor 
VIII binding antibodies (by ELISA) and has not developed any 
detectible antibody to factor VIII despite his extensive treatment 
with canine factor VIII while at the University of North Caro-
lina. The dog was fertile and generated a litter with 5 confirmed 
female carriers of hemophilia A, as is expected for a sex-linked 
disorder.
Materials and Methods
Animals. All animals were handled in strict accordance with 
the USDA regulations and the standards described in the 2010 
Guide for the Care and Use of Laboratory Animals (http://grants.nih.
gov/grants/olaw/Guide-for-the-Care-and-Use-of-Laboratory-
Animals.pdf). All procedures and protocols were in accordance 
with institutional guidelines and approved by the IACUC at the 
University of North Carolina at Chapel Hill (Animal Subject As-
surance no. A3410-01).
Genomic DNA isolation. DNA was prepared from whole blood 
anticoagulated with EDTA by using the Gentra Puregene Blood 
Kit (Qiagen, Valencia, CA). DNA was stored in 10 mM Tris, 1 mM 
EDTA (pH 8.0) at –20 °C after purification.
Preparation of cDNA for intron 22 inversion analysis. mRNA 
was prepared from peripheral blood mononuclear cells (purified 
from EDTA-anticoagulated whole blood) by using a Versagene 
RNA Purification Kit (Gentra Systems), and DNA was eliminated 
from the preparation by using DNase I (Sigma, St Louis, MO). 
cDNA was produced by reverse transcription of mRNA (High 
Capacity cDNA Reverse Transcriptase Kit, Life Technologies, 
Carlsbad, CA).
PCR amplification of genomic DNA and cDNA. PCR ampli-
fication was performed as described previously,41 by using an 
automated thermal cycler and AmpliTaq enzyme (Perkin-El-
mer Cetus, Norwalk, CT). Primers for PCR analysis are listed 
in Table 2.
DNA sequencing and analysis. Amplified PCR fragment DNA 
was sequenced directly by using a capillary sequencer (Prism 
3100, ABI, Waltham, MA). Sequence data were analyzed by using 
Sequencher software (Gene Codes, Ann Arbor, MI). Factor VIII 
sequences from our hemophilia A dog and normal dogs were 
compared with current GenBank submissions by using the Entrez 
Table 1. Results of baseline coagulation laboratory studies in the subject dog
Result Normal reference range (canine)
Prothrombin time 12.5 s 11–15.5 s
Activated partial thromboplastin time 32.4 s 8.5–15.5 s
Thrombin clotting time 6.5 s no reference range
Fibrinogen 310 mg/dL 150–490 mg/dL
Factor VIII (activity) <0.3% (chromogenic assay) no reference range
Von Willebrand factor (antigen) 94% 70%—180%
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samples displayed no inhibition of factor VIII activity (less than 
0.8 Bethesda inhibitor assay units). Similarly, ELISA measurement 
of factor VIII binding antibodies on the same samples showed no 
change in baseline IgG2 antibody levels (approximately 250 ng/
mL) in all samples.
Discussion
Our investigation revealed a point mutation in the canine factor 
VIII gene that creates a termination codon in place of arginine 577 
tor VIII cDNA sequence including exons 22 and 23. As expected, 
this portion of the canine factor VIII cDNA did not amplify in the 
dog with hemophilia A due to intron 22 inversion.
Conversely, PCR with primers from canine factor VIII exon 22 
and the novel ch8 sequence (AF361485) seen in the Chapel Hill 
intron 22 inversion mutation transcript failed to amplify in ge-
nomic DNA from a normal dog and the subject of this study but 
did amplify from cDNA derived from a descendant of the Chapel 
Hill hemophilia A dog, as expected (Figure 1 B). The sequence 
of the 200-bp amplimer derived from the Chapel Hill dog with 
intron 22 inversion hemophilia A corresponded exactly to that 
previously described31 (that is, normal exon 22 sequence followed 
by ch8 sequence at the exon 22–exon23 boundary).
Together, these findings indicate the hemophilia A mutation in 
our subject was not the intron 22 inversion previously reported. 
We then proceeded to determine the nucleotide sequence of the 
factor VIII cDNA.
Sequence analysis of entire factor VIII gene from the subject 
dog. All 26 exons of the canine factor VIII gene were sequenced in 
the subject of this report. Aside from various polymorphisms in 
the nucleic acid sequence that have been seen in normal dogs6,24,31 
or would be predicted not to change the underlying amino-acid 
coding sequence (Table 3), the cDNA sequence contained a C-to-T 
transition at nucleotide 1786 that changes a CGA (arginine) codon 
in exon 12 to a TGA (stop) codon (Figure 2). The mutated nucleo-
tide is a member of a CpG dinucleotide, and the mutation elimi-
nates a TaqI restriction endonuclease cleavage site (TCGA) in the 
genomic DNA, as can occur with such transitions in hemophilia 
A and other diseases.13,37,39 The mutation also creates a new MluCI 
restriction endonuclease cleavage site (AATT). Figure 3 shows the 
results of MluCI digestion of a 150-bp amplimer containing the 
site of the mutation for the subject of our study as well as normal 
and heterozygous female carrier hemophilia A dogs, indicating 
the gain of a MluCI cleavage site in the subject of our study.
The DNA sequence of the subject hemophilia A dog contained 
two additional mutations (besides the stop codon) that altered the 
amino acid sequence of factor VIII. Both affected amino acids are 
in exon 14, an exon that is part of the B domain of the factor VIII 
protein, which is dispensable for coagulation factor activity. These 
variant forms (serine 909 and proline 1184) have both been seen 
in the normal dog factor VIII sequence and have no apparent sig-
nificance with regard to factor VIII activity (Table 3 and Figure 4).
Analysis for inhibitor antibodies to factor VIII in the subject dog. 
Tests for inhibitor antibodies to factor VIII were performed on 2 
samples from 2010 (shortly after the dog was diagnosed with he-
mophilia A) and on 2 samples from 2015 (after extensive exposure 
to factor VIII) by using a Bethesda inhibitor antibody assay. All 4 
Table 2. Oligonucleotide primers used to amplify genomic DNA and create cDNA from hemophilia A and normal dogs
Primer location Primer sequence Amplimer size (bp)
Canine factor VIII exon 22 5′-GATCTCTTGGCACCGATGAT-3′ 236
Canine factor VIII exon 23 5′-TGCAAACGGATGTACTGAGC-3′
Canine factor VIII exon 22 5′-TCCAGCCTCTACGTGTCTCA-3′ 200
ch8 (sequence following exon 22 in intron 22 inversion) 5′-TGGCTTTAAGCAGTGGACCT-3′
Canine factor VIII exon 12 5′-TGATGTCAGACAAGAGAAATGTCA-3′ 150
Canine factor VIII exon 12 5′-TGTGCATGATGTTAGAGAGTTGG-3′
Figure 1. (A) Amplification of exons 22 and 23 of the canine factor VIII 
cDNA. cDNA purified from a normal dog (N), the Chapel Hill intron 22 
inversion hemophilia A dog (i22i), and the subject of this report (S) un-
derwent PCR analysis using primers in exons 22 and 23. The expected 
length of the exon 22–23 product is 236 bp. (B) Amplification of canine 
factor VIII exon 22 and ch8 from genomic DNA. Genomic DNA purified 
from a normal dog (N), the Chapel Hill intron 22 inversion hemophilia 
A dog (i22i), and the subject of this report (S) underwent PCR analysis 
using primers in exons 22 and 23. The expected length of the exon 22–
ch8 product is 200 bp.
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in exon 12 of the normal factor VIII protein. This mutation has not 
been seen in previously characterized hemophilia A dogs, specifi-
cally the intron 22 inversion dogs characterized at Chapel Hill31 
or at Queens University (Ontario, Canada).24 We also detected 2 
additional polymorphisms (serine 909 and proline 1184) in the 
subject dog that have been seen in normal dogs and that do not 
result in reduced factor VIII activity or contribute to the hemo-
philia A phenotype.6
The subject dog’s factor VIII mutation (arginine 577→stop) 
replicates the equivalent point mutation (arginine 602→stop, 
nucleotide 1804) that has previously been seen in exon 12 of the 
factor VIII gene in humans with severe hemophilia A.37 Both this 
subject dog and humans with the corresponding mutation have 
severe hemophilia A, no detectable factor VIII activity, and no 
detectable factor VIII antigen circulating in the blood. Accord-
ing to the Factor VIII Variant Database (http://www.factorviii-
db.org/; formerly the Haemophilia A Mutation, Structure, Test 
and Resource Site),13 this mutation has been detected in at least 
20 individual human patients with severe hemophilia A from 
9 different countries; of the 20 patients reported therein, 11 are 
stated to lack inhibitor antibodies to factor VIII, 2 have inhibitor 
antibodies to factor FVIII, and there is no reported information 
on the remainder.3,7,9,19,25,27,29,30,36,37,42,46,51 The apparently spontane-
ous occurrence of this mutation in multiple individuals might 
be explained as a consequence of the inherent instability of CpG 
dinucleotides, which are prone to deamination of cytosine result-
ing in its transition to thymidine.8,50 It is therefore unsurprising 
that the first point mutation found to cause hemophilia A in dogs 
would be in a CpG dinucleotide sequence, as we describe in the 
current report.
We predict that a mutation at amino acid 577 of the canine fac-
tor VIII in which the arginine is converted to glutamine could 
occur by deamination in the cytosine in the opposite strand of 
Table 3. Summary of variants in canine factor VIII coding sequence of normal and hemophilia A dogs
Exon number
1 7 7 8 10 12 12 12 14 14 14 14 14 14 15 16 25
Nucleotide number in reference sequence 
(NM_001003212)
141 877 909 1094 1440 1774 1786 1807 2782 2868 2943 3608 4278 5086 5292 5490 6866
Predicted normal dog coding sequence 
(XM_005640988.2) from dog X chromo-
some genomic sequence (NW_003726126.1)
c a a a t t c a a t g c a a c g g
mRNA from kidney and spleen 
(NM_001003212) and liver (reference 24) of 
normal dog
t g g g a c c g g c a t g g t a a
EST DN369010.1 (nucleotides 5013–5653) – - - - - - - - - - - - - a t g -
Male hemophilia A dog (current study) c a a a t t t a a t g c a a c g g
Heterozygous normal female dog 
(current study)
c/t a a a t t c a a/g t g/a c/t a a c/t g g
Amino acid change syn R>G syn N>G N>K F>L R>X N>D S>G syn syn P>L syn N>D syn syn G>D
syn, synonymous
Figure 2. Nucleotide sequences of factor VIII cDNA from a normal dog 
and a hemophilia A dog. The hemophilia A dog shows substitution of 
T for C (resulting in a new stop codon) at position 1768 (Arg577) of the 
factor VIII cDNA.
DNA (for example, CGA→CAA, Arg→Gln). Instability of a CpG 
dinucleotide has been shown to convert arginine to either a stop 
codon or to glutamine (depending on which DNA strand under-
goes cytosine deamination) in the factor VIII gene in humans at 
a different arginine (amino acid 2307 in exon 26) of the human 
factor VIII protein.16 The severity of the bleeding phenotype that 
might result from a mutation leading to conversion of arginine to 
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Dogs with severe hemophilia A, like humans, may develop 
neutralizing antibodies (inhibitors) to factor VIII after exposure to 
normal factor VIII through replacement therapy to treat bleeding 
episodes or as prophylaxis against bleeding. This particular dog 
has not, thus far, demonstrated evidence of an inhibitor antibody 
despite 72 treatments with canine factor VIII for bleeding (40,168 
units of recombinant B-domain and 2560 units of plasma-derived 
canine factor VIII over 5 y). No prediction of susceptibility to in-
hibitor development can be made from the (negative) results of 
a single dog, but it would be informative to see whether other 
hemophilia A dogs with this mutation made inhibitor antibodies, 
as occurs in some members of the 2 dog colonies with intron 22 
inversions.6,24,31 The type of genetic mutation that causes hemo-
philia A in humans seems to be a strong predictor of the risk to 
develop inhibitors after exposure to factor VIII protein.17,37 This 
same scenario is likely to be the case for dogs with hemophilia 
A and can now be tested in dogs with the mutation described in 
this report. Furthermore, changes in the factor VIII nucleic acid 
sequence that do not cause hemophilia but that change the amino 
acid sequence of the factor VIII protein have recently been argued 
to contribute to the risk of inhibitor antibody development when 
patients with hemophilia A are exposed to factor VIII that does 
not match their underlying sequence.47 With that understanding, 
dogs with the hemophilia A mutation that we describe here may 
ultimately prove to be useful animal models (along with those 
with the intron 22 gene inversion) in which to test this hypothesis 
through provocative transfusion strategies and characterization 
of the specificity of antibodies that arise against canine factor VIII 
after such maneuvers.
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